Tags

Type your tag names separated by a space and hit enter

Prevention of spinal bone loss by potassium citrate in cases of calcium urolithiasis.
J Urol. 2002 Jul; 168(1):31-4.JU

Abstract

PURPOSE

We determine if potassium citrate treatment stabilizes spinal bone density among patients with recurrent calcium oxalate nephrolithiasis.

MATERIALS AND METHODS

We studied a group of 16 men and 5 women with stones taking potassium citrate from 11 to 120 months. They represented all patients from the Stone Clinic who took potassium citrate alone for at least 11 months. L2-L4 bone mineral density data before and after potassium citrate treatment were retrieved retrospectively and analyzed.

RESULTS

In the combined group L2-L4 bone mineral density increased significantly by 3.1% over mean duration of 44 months. Z score, corrected for age matched normal values, increased significantly by 3.8%. Urinary pH, citrate and potassium increased significantly during treatment but urinary calcium did not change.

CONCLUSIONS

Potassium citrate, a commonly used drug for the prevention of recurrent nephrolithiasis, may avert age dependent bone loss. Spinal bone density increased in most patients when it normally decreases.

Authors+Show Affiliations

Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, Texas, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

12050486

Citation

Pak, Charles Y C., et al. "Prevention of Spinal Bone Loss By Potassium Citrate in Cases of Calcium Urolithiasis." The Journal of Urology, vol. 168, no. 1, 2002, pp. 31-4.
Pak CY, Peterson RD, Poindexter J. Prevention of spinal bone loss by potassium citrate in cases of calcium urolithiasis. J Urol. 2002;168(1):31-4.
Pak, C. Y., Peterson, R. D., & Poindexter, J. (2002). Prevention of spinal bone loss by potassium citrate in cases of calcium urolithiasis. The Journal of Urology, 168(1), 31-4.
Pak CY, Peterson RD, Poindexter J. Prevention of Spinal Bone Loss By Potassium Citrate in Cases of Calcium Urolithiasis. J Urol. 2002;168(1):31-4. PubMed PMID: 12050486.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prevention of spinal bone loss by potassium citrate in cases of calcium urolithiasis. AU - Pak,Charles Y C, AU - Peterson,Roy D, AU - Poindexter,John, PY - 2002/6/7/pubmed PY - 2002/7/9/medline PY - 2002/6/7/entrez KW - Non-programmatic SP - 31 EP - 4 JF - The Journal of urology JO - J. Urol. VL - 168 IS - 1 N2 - PURPOSE: We determine if potassium citrate treatment stabilizes spinal bone density among patients with recurrent calcium oxalate nephrolithiasis. MATERIALS AND METHODS: We studied a group of 16 men and 5 women with stones taking potassium citrate from 11 to 120 months. They represented all patients from the Stone Clinic who took potassium citrate alone for at least 11 months. L2-L4 bone mineral density data before and after potassium citrate treatment were retrieved retrospectively and analyzed. RESULTS: In the combined group L2-L4 bone mineral density increased significantly by 3.1% over mean duration of 44 months. Z score, corrected for age matched normal values, increased significantly by 3.8%. Urinary pH, citrate and potassium increased significantly during treatment but urinary calcium did not change. CONCLUSIONS: Potassium citrate, a commonly used drug for the prevention of recurrent nephrolithiasis, may avert age dependent bone loss. Spinal bone density increased in most patients when it normally decreases. SN - 0022-5347 UR - https://www.unboundmedicine.com/medline/citation/12050486/Prevention_of_spinal_bone_loss_by_potassium_citrate_in_cases_of_calcium_urolithiasis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0022-5347(05)64825-2 DB - PRIME DP - Unbound Medicine ER -